Board Of Directors

Meet our Board.

Our board of directors is made up of healthcare leaders, innovative scientists, and more. They possess deep expertise in biopharmaceuticals, healthcare, commercial and operational leadership, finance, internal controls, senior management, internal medicine, HIV/AIDS, virology, and other disciplines. Board members meet regularly to maintain and accelerate the business’ trajectory in bringing our innovative biopharmaceutical therapeutics to the market. Here are their stories.

Board Of Directors Header Image

Frank Torti, MD

Dr. Torti has served as Chairman of our Board since November 2018. Dr. Torti has served as the Vant Chair of Roivant Sciences, Inc. (“RSI”), a wholly-owned subsidiary of Roivant, since January 2020. In this capacity he serves as Chairman, CEO, or Executive Chairman of the board of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. From its founding in November 2022 to the close of its sale in December 2023, Dr. Torti served as Chief Executive Officer of Telavant, which was acquired by Roche for over $7 billion. Dr. Torti previously served as Vant Investment Chair of RSI. Prior to joining RSI, Dr. Torti served as a Partner of New Enterprise Associates (“NEA”), specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical &Genetic Economics in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials.

Dr. Torti presently serves as Executive Chair of the board of directors of Immunovant, Inc. (Nasdaq: IMVT). Dr. Torti previously served on the boards of directors of Urovant Sciences Ltd. and Myovant Sciences Ltd. During his career he has served on the boards of directors of approximately thirty development and commercial stage public and private healthcare companies. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.

Michael J. McElhaugh
Interim President and Chief Executive Officer and Director

Mr. McElhaugh joined Arbutus in July 2014 and has served as our Interim President, Chief Executive Officer, and Director since January 2024. Prior to this, Mr. McElhaugh served as our Chief Operating Officer and as our Chief Business Officer. Mr. McElhaugh has more than 20 years of scientific, strategic, transactional, and commercial experience spanning various operating roles within the pharmaceutical industry. Mr. McElhaugh joined Arbutus when it merged with OnCore Biopharma where he was a co-founder and served as its Chief Operating Officer. Previously, he was the Director, Hepatitis C Worldwide Commercialization at Bristol-Meyers Squibb. Prior to Bristol-Myers Squibb, Mr. McElhaugh was the Director, Business Development and Market Analytics at Pharmasset, Inc. and remained in that role following the acquisition by Gilead Sciences Inc. Mr. McElhaugh also held various positions at Viropharma, Inc. and at Merck and Co., Inc. Mr. McElhaugh received his B.S. degree from St. Joseph’s University, his M.S. degree from Thomas Jefferson University and his M.B.A. degree from the Johnson Graduate School of Management at Cornell University.

Daniel Burgess
Independent Director

Mr. Burgess has served as a director since March 2017. He is currently Chairman and Chief Executive Officer of Pulmocide Ltd. He also serves as a Venture Partner at SV Health Investors, is Chairman of the Board of Nabriva Therapeutics plc and Cidara Therapeutics (Nasdaq: CDTX) and several private biotechnology companies. Mr. Burgess is also Chairman of the Joint Oversight Board of CARB-X, a global non-profit partnership dedicated to addressing issues of anti-bacterial resistance. Prior to his current roles, Mr. Burgess was President and CEO of Rempex Pharmaceuticals, a company he co-founded and subsequently sold to the Medicines Company and was acting Chief Executive Officer of Therini Bio, Inc. Prior to Rempex, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., which was acquired by Aptalis Pharma Inc. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.

Richard C. Henriques
Independent Director

Mr. Henriques has served as a director since December 2014. He is currently a Senior Fellow at the University of Pennsylvania with a focus on impact investing. He formerly served as Chief Financial Officer for the Bill & Melinda Gates Foundation. In this role, Mr. Henriques was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program related investments and information technology. Mr. Henriques’ background includes more than 25 years working at Merck & Co., Inc. (NYSE: MRK). During this time, he served as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer, among other roles. Mr. Henriques currently serves as a member of the board of directors for the International Vaccine Institute, The Franklin Institute, Heritage Conservancy, Delaware Canal 21 (dedicated to preserving the 60 mile Delaware Canal), and Fisherman’s Mark (providing social services in Lambertville, NJ). He also serves on the board of Cabaletta Bio (Nasdaq: CABA), which is focused on discovery and development of therapies for B cell-mediated autoimmune diseases. He holds a B.A. in Oriental Studies from the University of Pennsylvania and an M.B.A. with a concentration in Finance from The Wharton School.

Keith Manchester, MD
Independent Director

Dr. Manchester has served as a director since March 2015. Dr. Manchester is a partner and the Head of Life Sciences for QVT Financial LP (“QVT”), an investment firm. He focuses on investments in life sciences companies. Dr. Manchester also serves as a director of Kriya Therapeutics, Inc., Roivant Sciences Ltd. (Nasdaq: ROIV) and Roivant Sciences, Inc. Dr. Manchester previously served as a director of Myovant Sciences Ltd. (NYSE:MYOV) and on the Supervisory Board of Medigene AG (OTCMKTS: MDGEF). Prior to joining QVT, Dr. Manchester was Vice President of Business Development and Director of Business Development at Applied Molecular Evolution, Inc., a biotechnology company. In prior roles, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm and an investment banker in the healthcare group at Goldman, Sachs & Co. Dr. Manchester received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.

James Meyers
Independent Director

Mr. Meyers has served as a director since October 2018. He also serves as a Board Member for CytomX Therapeutics (Nasdaq: CTMX) and Sangamo Therapeutics (Nasdaq:SGMO). Mr. Meyers is President and Chief Executive Officer of IntraBio Ltd., a privately held biopharmaceutical company with a late-stage drug pipeline that includes treatment for genetic and neurodegenerative diseases. In addition, Mr. Meyers has served as a Senior Advisor to the Boston Consulting Group, and has served as a Senior Advisor to Gilead Sciences, Inc. (“Gilead”) (Nasdaq: GILD) since his retirement from Gilead in February 2018. During his tenure at Gilead, Mr. Meyers was one of a relatively small group of executives who were instrumental in transitioning the company from an innovative start-up to one of the most successful biopharmaceutical organizations in the world. Prior to his advisory role, Mr. Meyers served as Gilead’s Executive Vice President of Worldwide Commercial Operations, responsible for all commercial activities including pricing and market access. Mr. Meyers also led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutics areas of HCV and HIV. Prior to Gilead, Mr. Meyers served in roles of increasing responsibility at both Zeneca Pharmaceuticals and Astra U.S.A. Mr. Meyers also serves on the Board of Pulmocide Ltd., a privately held biopharmaceutical company focusing on the discovery and development of inhaled medicine for the treatment of life-threatening fungal and viral infections of the respiratory tract. Mr. Meyers received his B.A. in Economics from Boston College.

Melissa V. Rewolinski, PhD
Independent Director

Dr. Rewolinski has served as a director since July 2023. Dr. Rewolinski has served as principal of MVR Consulting since August 2018, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held several senior level research and development positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and was a member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began her career at Pharmacia & Upjohn as a post-doctoral research scientist. She currently serves as a board member for American Type Culture Collection (ATCC) and served as a member of the board of directors of Lannett Company, Inc. from July 2019 to July 2023. Dr. Rewolinski earned a doctorate degree in organic chemistry and Bachelor of Science degree in chemistry, magna cum laude, from Rice University.



Learn about our organization’s strong leadership team.

Meet our Leadership Team

Meet Our Scientific Advisors

Scientific Advisors

Discover the scientists providing us their guidance and advisory.

Meet our Scientific Advisors